Considering Titanium Dioxide Regulatory Changes

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3

EFSA’s evaluation of risk in food products raises implications for drug product formulations.

titanium dioxide

Kateryna Kon/Adobe.Stock.com

Titanium dioxide is widely used for adding opacity and brightness in many products. A May 2021 evaluation from the European Food Safety Authority (EFSA), which declared that titanium dioxide is unsafe for food products, alarmed other industries that rely on the ingredient. Although changes are not required in pharmaceutical products, some supplement and drug manufacturers and their suppliers have considered potential alternatives. 

Read this article in Pharmaceutical Technology’s Regulatory Sourcebook eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 8-9

Citation

When referring to this article, please cite it as J. Markarian, “Considering Titanium Dioxide Regulatory Changes,” Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).

Articles in this issue
prefilled syringes are combination drug-device products
Understanding Combination Product Regulations
titanium dioxide
Considering Titanium Dioxide Regulatory Changes
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Changing the Course of Drug Shortages
Changing the Course of Drug Shortages
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach Image: ipopba - Stock.adobe.com
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices. Image: ipopba - Stock.adobe.com
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Industry Organizations Assist Pharma During the Pandemic and Beyond
Industry Organizations Assist Pharma During the Pandemic and Beyond
EU's Pharma Strategy
Mapping Out Pharma’s Regulatory Future in Europe
Recent Videos
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

USP Opens Advanced Technology Lab in Maryland

Susan Haigney
June 4th 2025
Article

The new lab will be used to develop and scale innovations for the production of medicines and to help secure the supply chain.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Aerial of UC Berkeley Campus | Image Credit: © coralimages - stock.adobe.com

UC Berkeley Awards $200K Venture Grant to HypO2Regen Therapeutics

Patrick Lavery
June 3rd 2025
Article

The grant encompasses $100,000 each from the Life Sciences Entrepreneurship Center and Berkeley SkyDeck, with SkyDeck having the option to invest an additional $100,000.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

inscription on the courthouse | Image Credit: © bluraz - stock.adobe.com

Eisai Wins Judgment Against Shilpa Over Sale of Lenvatinib Mesylate Generic

Patrick Lavery
June 2nd 2025
Article

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

Cambridge, MA, USA - June 29, 2022: Moderna logo is seen at the entrance to its headquarters in Cambridge, Massachusetts. Moderna, Inc., is an American pharmaceutical and biotechnology company. | Image Credit: © Tada Images - stock.adobe.com

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE

Patrick Lavery
June 2nd 2025
Article

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.